Paloma Partners’s Kyntra Bio KYNB Stock Holding History

Paloma Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-570	Closed	-$495K	–	1923
2021 Q1	$495K	Buy	+570	New	+$607K	0.01%	1134
2020 Q1	–	Sell	-723	Closed	-$775K	–	1496
2019 Q4	$775K	Buy	723 +105	+17%	+$107K	0.01%	1114
2019 Q3	$571K	Buy	+618	New	+$679K	0.01%	1073
2018 Q2	–	Sell	-500	Closed	-$577K	–	1807
2018 Q1	$577K	Buy	500 +285	+133%	+$375K	0.01%	1289
2017 Q4	$255K	Buy	+215	New	+$270K	﹤0.01%	1615

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's KYNB Position: Q2 2021 in Review

Paloma Partners sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 570 shares — an estimated $495K sold.

Paloma Partners first reported a position in KYNB in Q4 2017 and held it in 5 quarters. The position peaked at $775K in Q4 2019. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

Paloma Partners reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
Paloma Partners sold 570 Kyntra Bio shares in Q2 2021, an estimated $495K.
Paloma Partners first reported a position in Kyntra Bio in Q4 2017 and held it in 5 quarters.
Paloma Partners's Kyntra Bio position peaked at $775K in Q4 2019.
174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Paloma Partners's 13F filing for Q2 2021, filed 16 Aug 2021.